Inner Mongolia Jinyu Group Co., Ltd. in biopharmaceuticals.

Biopharmaceutical is the core industry of the company. At present, the company has two biopharmaceutical companies, namely Jinyu Ling Bao Biopharmaceutical Co., Ltd. and Yangzhou AIA Biopharmaceutical Co., Ltd.

Jinyu Ling Bao Biopharmaceutical Co., Ltd. is a high-tech enterprise integrating R&D, production and sales. Its predecessor was Inner Mongolia Biopharmaceutical Factory, which was founded in 1958. It is one of the five designated production enterprises designated by the Ministry of Agriculture to produce foot-and-mouth disease vaccine. Ling Bao company is located in the production of foot-and-mouth disease cattle, sheep and pigs, as well as swine fever and spleen disease. Now it has three production workshops that have passed GMP certification of the Ministry of Agriculture, as well as supporting inspection and testing laboratories, closed pens for raising pigs, cattle and small animals, and power and energy supply systems. Because of its good scale and safety conditions, the laboratory animal room can not only meet the needs of pure inspection, security inspection and effective inspection of enterprises' own products, but also often provide services for the experimental projects of the Animal Disease Prevention and Control Center of the Ministry of Agriculture and the China Veterinary Drug Control Institute. The factory covers a total area of 220,000 square meters, including a building area of 59,900 square meters, a purification area of 130 10 square meters and a negative pressure area of 4,720 square meters. Technicians account for 70% of the total number of people in the factory. At present, the annual output of foot-and-mouth disease can reach 2.4 billion ml.

R&D has been one of the company's priorities for many years. At present, it has close cooperation with the Key Open Laboratory of Tropical and Subtropical Animal Virology of the Ministry of Agriculture, China Agricultural University, Henan Agricultural University, Fudan University, Veterinary Research Institute of the Academy of Military Medical Sciences, Yangzhou University, China Veterinary Drug Monitoring Institute, National Animal Disease Control Center and other scientific research units in the fields of genetically engineered vaccines, vaccine heat-resistant protective agents and new product research and development.

After eight years of rapid development, the product sales network has covered 3 1 province (city, autonomous region) in China. Since 1999, the market share has increased year by year. In 2006, the annual sales revenue exceeded 300 million yuan, maintaining the position of the top three in the industry.

Jinyu Ling Bao Bio-pharmaceutical Co., Ltd. was rated as an advanced enterprise in Inner Mongolia Autonomous Region, a first-class household with profits and taxes in Hohhot, and an AAA credit enterprise. In 2002, the company was rated as the top 50 animal health care industry in China by the Ministry of Agriculture, and the first GMP workshop of virulent inactivated vaccine certified by the Ministry of Agriculture was built in China, ranking second in the country in biological vaccine products and market share. In 2004, the company was rated as the top 20 private enterprises in Hohhot, the top 20 taxpayers in Hohhot and the top 20 manufacturers in Hohhot. In 2007, Jinyu Ling Bao Biopharmaceutical Co., Ltd. was rated as one of the top ten famous scientific and technological products by the municipal government.

Yangzhou AIA Biopharmaceutical Co., Ltd. is a biopharmaceutical company successfully acquired by Jinyu Group in 2007, which is an important step for Jinyu Group to optimize its industrial layout and expand its development. The company is mainly engaged in the production and sales of porcine blue ear disease vaccine, and has GMP production workshop certified by the Ministry of Agriculture. Up to now, the annual production capacity of porcine blue ear disease vaccine is 300 million ml, and the market share is over 30%. Ranked first.